- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03371134
Role of HIF-1α in Skeletal Muscle Aging (HIF)
Role of Hypoxia Inducible Factor-1α (HIF-1α) in Skeletal Muscle Aging
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Deficits in skeletal muscle function exist during aging and muscular dystrophy, and suboptimal function has been related to factors such as atrophy, excessive inflammation and fibrosis. Sarcopenia is the age-related loss of skeletal muscle mass and function. It is now recognised as a major clinical problem for older people and research in the area is expanding exponentially. This interest stems from the fact that sarcopenia is both common and associated with serious health consequences in terms of frailty, disability, morbidity and mortality. The age-related loss of human skeletal muscle mass is due to a decrease in myofibre size and number with the loss of both fast and slow type myofibres, although the loss of fast myofibres tends to start earlier, at ∼70 years. Many factors influence the decrease in muscle mass. A significant contributor is an anabolic resistance of older skeletal muscle to protein nutrition as seen during immobilisation which can be ameliorated at least in part by resistance exercise and dietary supplementation. Other intensive areas of research are related to the loss of innervation and oxidative damage. Moreover, ineffective muscle regeneration underlies each condition and has been attributed to a deficit in myogenic potential of resident stem cells or satellite cells. It is now widely accepted that satellite cells, and generally adult stem cells, are normally quiescent and tend to reside in hypoxic areas of the tissue to preserve their undifferentiated state. To govern these processes, cells have developed a very complex machinery that is mainly regulated by a group of transcription factors known as hypoxia-inducible factors (HIFs). In particular, several observations support the idea that oxygen deprivation and HIF-1a may play a key role during ischemia to activate the regeneration process, which, after an initial hypoxic insult, needs to proceed under normoxia. On these bases, in this study we will investigate the role of HIF-1a in skeletal atrophy during aging.
In particular, we will isolate satellite cells from muscular biopsies harvested from old sarcopenic patients and from young patients. The, we will measure HIF-1a levels and we will compare them.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients will be selected and evaluated in the primary care clinic. The eligibility criteria will be checked 2-4 weeks before surgery.
Muscular biopsies will be harvested from discarded material during surgery.
Description
Inclusion Criteria:
- Sarcopenic patients (measured by DXA) affected by hip osteoarthritis, developmental dysplasia of the hip or hip fracture and undergoing hip replacement surgery (for the sarcopenic group)
- Patients affected by traumatic ACL tears and undergoing ACL reconstruction surgery (for the control group)
- Patients between 18 and 35 years old (for the control group)
- Patients between 65 and 90 years old (for the sarcopenic group)
- 18 ≤ Body Mass Index (BMI) ≤ 30 kg/m2
Exclusion Criteria:
- Diseases that can affect bone or muscle metabolism
- Pharmacological therapies that can interact with bone or muscle metabolism
- Bone metastases
- Bone infections
- HIV, hepatitis B virus, hepatitis C virus or Treponema pallidum positivity
- BMI ≥30kg/m2
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sarcopenic group
Harvesting of muscular biopsies Muscular biopsies will be harvested from old sarcopenic patients undergoing hip replacement surgery
|
Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
|
Control group
Harvesting of muscular biopsies Muscular biopsies will be harvested from young patients undergoing Anterior Cruciate Ligament (ACL) reconstruction surgery
|
Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of HIF-1a expression levels in satellite cells isolated from sarcopenic and young
Time Frame: 1 year
|
Western blot analysis of HIF-1a levels and of its downstream targets (Vascular Endothelial Growth Factor: VEGF, phosphoglycerate kinase: PGK, Prolylhydroxilases: PHD2)
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of sarcopenic profile in satellite cells harvested from old sarcopenic patients
Time Frame: 6 months
|
Real Time polymerase chain reaction: PCR analysis of MURF1 and atrogin1 (markers of muscular aging)
|
6 months
|
Correlation of HIF-1a levels with the degree of sarcopenia in the satellite cells of old sarcopenic patients
Time Frame: 1 year
|
chromatin immunoprecipitation: ChiP seq analysis of HIF-1a downstream targets
|
1 year
|
Evaluation of differences in satellite cells number between young and old patients
Time Frame: 6 months
|
To evaluate differences in cell number two different immunohistochemical analyses will be used in order to obtain a ratio: 1. Immunofluorescence for PAX7 (satellite cell markers) and 2. BrdU will be performed and the ration between PAX7 positive cells and bromodeoxyuridine: BrdU positive cells will be calculated.
|
6 months
|
Evaluation of HIF-1a stabilization on satellite cells treated with PHDs inhibitors
Time Frame: 1 year
|
Prolylhydroxilases: PHDs inhibitors (FG-4592 e PLG) will be tested in vitro to analyze HIF-1a downstream targets (Vascular Endothelial Growth Factor: VEGF, phosphoglycerate kinase: PGK, Prolylhydroxilases: PHD2) by real time PCR
|
1 year
|
Evaluation of satellite cell proliferation in cells treated with PHDs inhibitors
Time Frame: 1 year
|
Prolylhydroxilases: PHDs inhibitors (FG-4592 e PLG) will be tested in vitro to analyze cell proliferation (RealTime Glow and CellTox kits)
|
1 year
|
Evaluation of satellite cell differentiation in cells treated with PHDs inhibitors
Time Frame: 1 year
|
Prolylhydroxilases: PHDs inhibitors (FG-4592 e PLG) will be tested in vitro to analyze cell differentiation (Immunofluorescence and Realt Time PCR analysis for differentiation markers: MyoD, Myogenin and Myosin Heavy Chain)
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Mangiavini, Dr, IRCCS Istituto Ortopedico Galeazzi
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HIF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on Harvesting of muscular biopsies
-
Nantes University HospitalUnknown
-
Cliniques universitaires Saint-Luc- Université...Completed
-
Ageless Regenerative InstituteWithdrawnNervous System Diseases | Multiple Sclerosis | Autoimmune Diseases of the Nervous System | Autoimmune DiseasesUnited States
-
NeuroGenerationWithdrawn
-
University of North Carolina, Chapel HillInterpace Diagnostics CorporationActive, not recruitingBarretts Esophagus With Dysplasia | Intramucosal AdenocarcinomaUnited States
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawn
-
Ageless Regenerative InstituteWithdrawnParkinson's DiseaseUnited States
-
Misr International UniversityAin Shams UniversityCompletedGingival Recession, LocalizedEgypt
-
I.M. Sechenov First Moscow State Medical UniversityRecruitingSoft Tissue AtrophyRussian Federation
-
Stanford UniversityThe University of Texas Health Science Center, Houston; University of RochesterTerminatedCholangiocarcinoma | Stricture; Bile DuctUnited States